Numinus Wellness: Important Updates on Annual Filings and Future Expectations

Numinus Wellness Provides Bi-Weekly Update on Annual Filings

Numinus Wellness Inc. (TSX: NUMI), a frontrunner in innovative mental health care, has recently updated its stakeholders on key developments regarding its annual filings. This announcement comes in light of the management cease trade order (MCTO) issued by the British Columbia Securities Commission due to delays in the filing of its audited annual financial statements, management discussion and analysis, and the annual information form for the financial year ending August 31, 2024.

On December 2, 2024, the British Columbia Securities Commission granted the MCTO, which restricts the Company’s CEO and CFO from trading shares until the required filings are submitted. Importantly, this management order does not impede shareholders from trading their stocks. During this interim period, Numinus has halted any buy-back activities related to its normal course issuer bid and is committed to not acquiring securities from insiders until the situation is resolved.

The delay in filing stems from unforeseen circumstances impacting the preparation of these documents. However, the Company expresses confidence that all required filings will be completed by January 28, 2025. Once finalized, Numinus will promptly announce the completion of these filings through a press release.

As part of its compliance with standard regulations, Numinus will also issue bi-weekly updates regarding its filing status, adhering to the guidelines set forth in National Policy 12-203. Since the previous announcement, the Company assures stakeholders that it has met all obligations under the alternative information guidelines and has not encountered any further defaults or insolvency issues.

The Board of Directors and management team are actively collaborating with accountants to ensure timely resolution of the outstanding filings. They remain transparent about their progress and accountability during this period, keeping an open line of communication with all stakeholders who have an interest in the Company’s developments.

Numinus is well-known for its pioneering work in mental health care, with a focus on developing effective treatments, including psychedelic-assisted therapies. This transformative approach is aimed at healing individuals suffering from a range of conditions such as depression, anxiety, and trauma, moving beyond merely managing symptoms.

As a notable player in the field of psychedelic therapy, Numinus is on a mission to integrate these innovative practices into mainstream clinical environments, offering hope and extensive support in mental health recovery processes. The Company’s commitment to transparency and regulatory compliance demonstrates its dedication not only to its shareholders but also to the broader mission of enhancing mental health and well-being through research and therapy.

As the situation unfolds, it will be critical for stakeholders to stay engaged with Numinus’ updates, particularly regarding the anticipated completion of the annual filings and the implications for the Company’s trading activities. The evolving landscape of mental health care and the role of psychedelics in therapeutic contexts continues to garner interest, marking Numinus as a pivotal figure in this sector.

For further information, stakeholders can visit Numinus’ official website or follow the Company on platforms like LinkedIn, Facebook, and Instagram for the latest updates and insights. It’s an exciting time in the world of mental health innovations, and Numinus appears poised for growth and adaptation in the face of current challenges.